全文获取类型
收费全文 | 7652篇 |
免费 | 451篇 |
国内免费 | 54篇 |
专业分类
耳鼻咽喉 | 74篇 |
儿科学 | 272篇 |
妇产科学 | 180篇 |
基础医学 | 1278篇 |
口腔科学 | 108篇 |
临床医学 | 599篇 |
内科学 | 1873篇 |
皮肤病学 | 178篇 |
神经病学 | 794篇 |
特种医学 | 147篇 |
外科学 | 631篇 |
综合类 | 23篇 |
预防医学 | 669篇 |
眼科学 | 156篇 |
药学 | 586篇 |
中国医学 | 37篇 |
肿瘤学 | 552篇 |
出版年
2024年 | 7篇 |
2023年 | 54篇 |
2022年 | 168篇 |
2021年 | 282篇 |
2020年 | 162篇 |
2019年 | 223篇 |
2018年 | 239篇 |
2017年 | 200篇 |
2016年 | 205篇 |
2015年 | 246篇 |
2014年 | 326篇 |
2013年 | 398篇 |
2012年 | 629篇 |
2011年 | 632篇 |
2010年 | 323篇 |
2009年 | 268篇 |
2008年 | 479篇 |
2007年 | 536篇 |
2006年 | 502篇 |
2005年 | 464篇 |
2004年 | 432篇 |
2003年 | 387篇 |
2002年 | 364篇 |
2001年 | 41篇 |
2000年 | 28篇 |
1999年 | 47篇 |
1998年 | 69篇 |
1997年 | 61篇 |
1996年 | 47篇 |
1995年 | 47篇 |
1994年 | 34篇 |
1993年 | 34篇 |
1992年 | 31篇 |
1991年 | 20篇 |
1990年 | 16篇 |
1989年 | 14篇 |
1988年 | 22篇 |
1987年 | 17篇 |
1986年 | 15篇 |
1985年 | 10篇 |
1984年 | 10篇 |
1983年 | 10篇 |
1982年 | 8篇 |
1981年 | 10篇 |
1980年 | 5篇 |
1978年 | 8篇 |
1977年 | 3篇 |
1976年 | 5篇 |
1975年 | 3篇 |
1974年 | 4篇 |
排序方式: 共有8157条查询结果,搜索用时 140 毫秒
91.
Luisa Knecht Jonas Folke Richard Dodel J. Alexander Ross Alexandra Albus 《Neurotherapeutics》2022,19(5):1489
The therapeutic strategies currently available for neurodegenerative diseases such as Parkinson’s disease target only the symptoms of the disease. Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy can be summarized as synucleinopathies, as they are all characterized by the aggregation and accumulation of alpha-synuclein (α-syn) in the brain. Targeting α-syn by its formation and progression opens a new and promising disease-modifying therapeutic strategy. Thus, several distinct immunotherapeutic approaches are currently being evaluated in clinical trials. The objective of this article is to review, from a biological perspective, the most important properties of these passive and active immunotherapies to point out their relevance and suitability for the treatment of synucleinopathies. Supplementary InformationThe online version contains supplementary material available at 10.1007/s13311-022-01288-7. 相似文献
92.
Jasna E. Deluce Luisa Cardenas Aly-Khan Lalani Saman Maleki Vareki Ricardo Fernandes 《Current oncology (Toronto, Ont.)》2022,29(7):5054
Prostate cancer remains one of the leading causes of cancer death in men worldwide. In the past decade, several new treatments for advanced prostate cancer have been approved. With a wide variety of available drugs, including cytotoxic agents, androgen receptor axis-targeted therapies, and alpha-emitting radiation therapy, identifying their optimal sequencing remains a challenge. Progress in the understanding of the biology of prostate cancer has provided an opportunity for a more refined and personalized treatment selection process. With the advancement of molecular sequencing techniques, genomic precision through the identification of potential treatment targets and predictive biomarkers has been rapidly evolving. In this review, we discussed biomarker-driven treatments for advanced prostate cancer. First, we presented predictive biomarkers for established, global standard treatments for advanced diseases, such as chemotherapy and androgen receptor axis-targeted agents. We also discussed targeted agents with recent approval for special populations, such as poly ADP ribose polymerase (PARP) inhibitors in patients with metastatic castrate-resistant prostate cancer with homologous recombination repair-deficient tumors, pembrolizumab in patients with high levels of microsatellite instability or high tumor mutational burden, and prostate-specific membrane antigen (PSMA) directed radioligand theragnostic treatment for PSMA expressing tumors. Additionally, we discussed evolving treatments, such as cancer vaccines, chimeric antigen receptor T-cells (CAR-T), Bispecific T-cell engagers (BiTEs), other targeted agents such as AKT inhibitors, and various combination treatments. In summary, advances in molecular genetics have begun to propel personalized medicine forward in the management of advanced prostate cancer, allowing for a more precise, biomarker-driven treatment selection with the goal of improving overall efficacy. 相似文献
93.
L Filippi P Fiorini M Daniotti S Catarzi S Savelli C Fonda L Bartalena A Boldrini M Giampietri R Scaramuzzo P Papoff F Del Balzo A Spalice G la Marca S Malvagia ML Della Bona G Donzelli F Tinelli G Cioni T Pisano M Falchi R Guerrini 《BMC pediatrics》2012,12(1):144
ABSTRACT: BACKGROUND: Despite progresses in neonatal care, the mortality and the incidence of neuro-motor disability after perinatal asphyxia have failed to show substantial improvements. In countries with a high level of perinatal care, the incidence of asphyxia responsible for moderate or severe encephalopathy is still 2--3 per 1000 term newborns. Recent trials have demonstrated that moderate hypothermia, started within 6 hours after birth and protracted for 72 hours, can significantly improve survival and reduce neurologic impairment in neonates with hypoxic-ischemic encephalopathy. It is not currently known whether neuroprotective drugs can further improve the beneficial effects of hypothermia. Topiramate has been proven to reduce brain injury in animal models of neonatal hypoxic ischemic encephalopathy. However, the association of mild hypothermia and topiramate treatment has never been studied in human newborns. The objective of this research project is to evaluate, through a multicenter randomized controlled trial, whether the efficacy of moderate hypothermia can be increased by concomitant topiramate treatment. METHODS: Term newborns (gestational age >= 36 weeks and birth weight >= 1800 g) with precocious metabolic, clinical and electroencephalographic (EEG) signs of hypoxic-ischemic encephalopathy will be randomized, according to their EEG pattern, to receive topiramate added to standard treatment with moderate hypothermia or standard treatment alone. Topiramate will be administered at 10 mg/kg once a day for the first 3 days of life. Topiramate concentrations will be measured on serial dried blood spots. 64 participants will be recruited in the study. To evaluate the safety of topiramate administration, cardiac and respiratory parameters will be continuously monitored. Blood samplings will be performed to check renal, liver and metabolic balance. To evaluate the efficacy of topiramate, the neurologic outcome of enrolled newborns will be evaluated by serial neurologic and neuroradiologic examinations. Visual function will be evaluated by means of behavioural standardized tests. DISCUSSION: This pilot study will explore the possible therapeutic role of topiramate in combination with moderate hypothermia. Any favourable results of this research might open new perspectives about the reduction of cerebral damage in asphyxiated newborns. Trial registration Current Controlled Trials ISRCTN62175998; ClinicalTrials.gov Identifier NCT01241019; EudraCT Number 2010-018627-25. 相似文献
94.
Outcome of children and adolescents with Down syndrome treated on Dana‐Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium protocols 00–001 and 05‐001
下载免费PDF全文
![点击此处可从《Pediatric blood & cancer》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Uma H. Athale Maneka Puligandla Kristen E. Stevenson Barbara Asselin Luis A. Clavell Peter D. Cole Kara M. Kelly Caroline Laverdiere Jean‐Marie Leclerc Bruno Michon Marshall A. Schorin Maria Luisa Sulis Jennifer J. G. Welch Marian H. Harris Donna S. Neuberg Stephen E. Sallan Lewis B. Silverman 《Pediatric blood & cancer》2018,65(10)
95.
Transient elastography for non‐invasive evaluation of post‐transplant liver graft fibrosis in children
下载免费PDF全文
![点击此处可从《Pediatric transplantation》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Tiziana Vinciguerra Andrea Brunati Ezio David Filomena Longo Michele Pinon Fulvio Ricceri Luisa Castellino Antonio Piga Maria Teresa Giraudo Francesco Tandoi Fabio Cisarò Dominic Dell Olio Giuseppe Isolato Renato Romagnoli Mauro Salizzoni Pier Luigi Calvo 《Pediatric transplantation》2018,22(2)
As graft survival in pediatric LT is often affected by progressive fibrosis, numerous centers carry out protocol liver biopsies. Follow‐up biopsy protocols differ from center to center, but all biopsies are progressively spaced out, as time from transplant increases. Therefore, there is a need for non‐invasive techniques to evaluate graft fibrosis progression in those children who have no clinical or serological signs of liver damage. Indirect markers, such as the APRI, should be relied on with caution because their sensitivity in predicting fibrosis can be strongly influenced by the etiology of liver disease, severity of fibrosis, and patient age. A valid alternative could be TE, a non‐invasive technique already validated in adults, which estimates the stiffness of the cylindrical volume of liver tissue, 100‐fold the size of a standard needle biopsy sample. The aims of this study were to evaluate the reliability of TE in children after LT and to compare both the TE and the APRI index results with the histological scores of fibrosis on liver biopsies. A total of 36 pediatric LT recipients were studied. All patients underwent both TE and biopsy within a year (median interval ‐0.012 months) at an interval from LT of 0.36 to 19.47 years (median 3.02 years). Fibrosis was assessed on the biopsy specimens at histology and staged according to METAVIR. There was a statistically significant correlation between TE stiffness values and METAVIR scores (P = .005). The diagnostic accuracy of TE for the diagnosis of significant fibrosis (F ≥ 2) was measured as the area under the curve (AUROC = 0.865), and it demonstrated that the method had a good diagnostic performance. APRI was not so accurate in assessing graft fibrosis when compared to METAVIR (AUROC = 0.592). A liver stiffness cutoff value of 5.6 kPa at TE was identified as the best predictor for a significant graft fibrosis (METAVIR F ≥ 2) on liver biopsy, with a 75% sensitivity, a 95.8% specificity, a 90% positive predictive value, and an 88.5% negative predictive value. These data suggest that TE may represent a non‐invasive, reliable tool for the assessment of graft fibrosis in the follow‐up of LT children, alerting the clinicians to the indication for a liver biopsy, with the aim of reducing the number of protocol liver biopsies. 相似文献
96.
Ignacio Ruiz del Olmo Izuzquiza Matilde Bustillo Alonso María Luisa Monforte Cirac Pedro Burgués Prades Carmelo Guerrero Laleona 《Anales de pediatría (Barcelona, Spain : 2003)》2017,86(3):115-121
Objective
To study the epidemiology, clinical features, diagnosis, therapeutic management, and outcome of non-tuberculous mycobacterial lymphadenitis in a paediatric population of Aragón (Spain).Material and methods
A retrospective study was conducted on patients under 15 years-old diagnosed with non-tuberculous mycobacterial lymphadenitis between the years 2000 and 2015. Inclusion criteria: patients with lymphadenitis and positive culture. Quantitative values are shown as mean, rank, and standard deviation, and qualitative data as frequencies.Results
Twenty-seven cases were registered, with a mean age of presentation of 39.9 months (range 10 months–8 years). The mean time between the symptoms onset and first consultation was 1.7 ± 1.1 months. The most frequent location was sub-maxilar in 17/27 cases (63%), on the right side in 59.3%, and size 2.96 ± 1.26 cm. Fistulae were observed in 16/27 cases. Tuberculin test was greater than 10 mm in 7/24 (29.1%). Microbiological cultures were positive for Mycobacterium avium in 14/27 (51.9%), Mycobacterium intracellulare 3/27 (11.1%), and Mycobacterium lentiflavum 3/27 (11.1%). Combined treatment of antibiotics and surgery was given in 16/27 cases (59.8%), medical treatment only in7/27 (25.9%), and surgical exeresis alone in 4/27 (14.8%). Two patients required a new surgery, and one showed severe neutropenia secondary to rifabutin. Only one case (3.7%) suffered from temporary facial palsy as sequel.Conclusions
The most frequent treatment was the combination of antibiotics and surgery. Delay in diagnosis seemed to be responsible for the limited number of exeresis as first option, only one for every seven patients. 相似文献97.
Luisa M. Cardenas Jasna E. Deluce Shahrukh Khan Omar Gulam Saman Maleki Vareki Ricardo Fernandes Aly-Khan A. Lalani 《Current oncology (Toronto, Ont.)》2022,29(8):5426
While surgical resection has remained the mainstay of treatment in early-stage renal cell carcinoma (RCC), therapeutic options in the advanced setting have remarkably expanded over the last 20 years. Tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor (VEGF-TKIs) and anti-programmed cell death 1 (PD-1)/anti-programmed death-ligand 1 (PD-L1)-based immune checkpoint inhibitors (ICIs) have become globally accepted options in the upfront metastatic setting, with different ICI-based combination strategies improving overall survival compared to single-agent Sunitinib. Although some patients benefit from long-term responses, most eventually develop disease progression. Ongoing efforts to better understand the biology of RCC and the different mechanisms of acquired resistance have led to the identification of promising therapeutic targets. Belzutifan, a novel agent targeting the angiogenic pathway involving hypoxia-inducible factors (HIFs), has already been approved for the treatment of early-stage tumors associated with VHL disease and represents a very promising therapy in advanced RCC. Other putative targets include epigenetic regulation enzymes, as well as several metabolites such as adenosine, glutaminase and tryptophan, which are critical players in cancer cell metabolism and in the tumor microenvironment. Different methods of immune regulation are also being investigated, including CAR-T cell therapy and modulation of the gut microbiome, in addition to novel agents targeting the interleukin-2 (IL-2) pathway. This review aims to highlight the emergent novel therapies for RCC and their respective completed and ongoing clinical trials. 相似文献
98.
Gabrielle Romain Paolo Strati Ali Rezvan Mohsen Fathi Irfan N. Bandey Jay R T. Adolacion Darren Heeke Ivan Liadi Mario L. Marques-Piubelli Luisa M. Solis Ankit Mahendra Francisco Vega Laurence J.N. Cooper Harjeet Singh Mike Mattie Adrian Bot Sattva S. Neelapu Navin Varadarajan 《The Journal of clinical investigation》2022,132(17)
99.
Zachary Alan Wilkinson MD Maria Luisa C. Policarpio-Nicolas MD 《Diagnostic cytopathology》2024,52(6):342-349
This report describes the cytologic features of a recently described MXD4::NUTM1-rearranged colonic sarcoma metastatic to the midclavicular soft tissue. Thirteen years ago, a 65-year-old woman presented with a cecal mass and subsequent liver mass. The cecal mass was diagnosed as malignant undifferentiated spindled and epithelioid neoplasm based on morphology and lack of tumor immunoreactivity with a panel of epithelial, smooth muscle, skeletal, melanoma, hematologic, and GIST markers. The liver mass showed morphologic and immunophenotypic similarity to the epithelioid component of the patient's cecal mass, albeit devoid of the spindled component. Fine needle aspiration of the midclavicular soft tissue mass showed singly scattered to clustered epithelioid to rhabdoid tumor cells with centrally to eccentrically located nuclei, prominent nucleoli, and moderate eosinophilic cytoplasm. Immunohistochemical stains performed on the concurrent biopsy showed the tumor cells were positive for NUT and negative for all other additional markers with retained normal expression of SMARCA2 and SMARCA4. Next-generation sequencing showed the presence of MXD4::NUTM1 gene fusion. Due to the identical cytomorphologic findings with the epithelioid component of the patient's prior cecal and liver masses, the tumor was deemed as consistent with a NUTM1-rearranged sarcoma. To our knowledge, this case represents the first reported cytologic features of a NUTM1-rearranged sarcoma on fine needle aspiration. Familiarity with the cytologic features, inclusion of this entity in the differential diagnosis of tumors with epithelioid and/or rhabdoid morphology, and performance of ancillary tests (immunohistochemistry and molecular) will be helpful in arriving at the right diagnosis. 相似文献
100.
Silvia Greco Stefania Manzi Luisa Molari Andrea Saccani Gianfranco Ulian Giovanni Valdr 《Materials》2023,16(1)
One of the main concerns in using natural materials in construction, such as bamboo, regards their durability. Ultra violet (UV)irradiation is claimed as a damaging agent; therefore, it is important to study its effect. Several studies have shown that bamboo components such as lignin are subjected to photochemical degradation, but it is not well understood how this affects the mechanical properties of bamboo. The aim of this paper is to explore the correlation between photodegradation and bamboo mechanical performance. Bamboo samples were exposed to accelerated UV ageing for different times (from 6 to 360 h) and then subjected to a four-point bending test. Since one of the ways to stabilize bamboo is to thermally treat it, the tests were conducted on natural untreated bamboo and treated bamboo with a traditional flame treatment. Modifications of the chemical features of the material were analyzed with Fourier Trasform Infra Red (FTIR) spectroscopy, while modifications of the morphological features were analyzed byEnvironmental Scanning Electron Microscopy ESEM and optical microscopy observations. The results show that the bending behavior of bamboo is not compromised by UV exposure up to 360 h. In fact, although a progressive degradation of lignin is reported and cracks in the fiber walls are highlighted from micrographs, no effects were found on the fiber length. 相似文献